Search research articles
Contact Us
Filters
Showing results (611-620 of 651) with videos related to
Page
of 66
Sort By:
Journal for Immunotherapy of Cancer
|
February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Cancer Discovery
|
June 18, 2025
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers
No-Joon Song, Juan Xie, Kyeong Joo Jung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 8, 2025
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database
David P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 28, 2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016
Daniel S W Tan, Sue S Yom, Ming S Tsao, et al.
Journal of Cancer
|
June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors
Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 1, 2025
Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423-1440]"
David P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancers
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
Page
of 66
Search research articles
Search
Showing results (611-620 of 651) with videos related to
Sort By:
Page
of 66
Journal for Immunotherapy of Cancer
|
February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal for Immunotherapy of Cancer
|
February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
Cancer Discovery
|
June 18, 2025
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers
No-Joon Song, Juan Xie, Kyeong Joo Jung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 8, 2025
The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database
David P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 28, 2016
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016
Daniel S W Tan, Sue S Yom, Ming S Tsao, et al.
Journal of Cancer
|
June 22, 2026
Association between obesity, sex, medical comorbidities, and survival in cancer patients treated with immune checkpoint inhibitors
Mingjia Li, Daniel J Spakowicz, Songzhu Zhao, et al.
The Lancet. Oncology
|
January 21, 2021
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 1, 2025
Corrigendum to "The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423-1440]"
David P Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancers
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
Page
of 66